Non-Hodgkin's Lymphoma
News
Idiotype Vaccine Improves Disease-free Survival in Patients with Follicular Lymphoma
(06/08/2009)
BiovaxID, an individualized tumor-specific protein vaccine, prolongs disease-free survival in patients with advanced follicular lymphoma who experience complete remission for six months or longer following first-line treatment with the chemotherapy regimen PACE, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Additional Evidence That Antibiotics Are Effective Against Gastric MALT Lymphomas
(05/29/2009)
According to the results of a study published in the Annals of Oncology, antibiotic treatment of Helicobacter pylori infection results in a high rate of long-term survival among patients with localized, gastric MALT lymphoma.
Maintenance Rituxan® Prolongs Survival in Advanced Indolent Lymphoma
(03/24/2009)
Maintenance Rituxan® (rituximab) given after standard chemotherapy significantly prolongs progression-free survival (PFS) in patients with advanced-stage indolent non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.
Pralextrate Continues to Show Benefit in Treatment of Peripheral T-Cell Lymphoma
(02/10/2009)
According to the final results of a Phase II clinical trial, 27% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma) experienced a complete or partial disappearance of detectable cancer following treatment with the investigational drug pralatrexate; the median duration of response was over nine months.
Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
(02/06/2009)
A Report from the 2008 Meeting of the American Society of Hematology
More
Non-Hodgkin's Lymphoma
Cancer News...